1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,132 | 0,165 | 29.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.04. | BRII-B (02137): NOTIFICATION LETTER AND REQUEST FORM FOR NON-REGISTERED SHAREHOLDERS | - | HKEx | ||
| 23.04. | BRII-B (02137): NOTIFICATION LETTER AND CHANGE REQUEST FORM FOR REGISTERED SHAREHOLDERS | 1 | HKEx | ||
| 23.04. | BRII-B (02137): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 1 | HKEx | ||
| BRII BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 23.04. | BRII-B (02137): FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING | - | HKEx | ||
| 23.04. | BRII-B (02137): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 23.04. | BRII-B (02137): (1) PROPOSALS FOR ADOPTION OF THE AUDITED CONSOLIDATED FINANCIAL STATEMENTS; (2) RE-ELECTION OF RETIRING DIRECTORS; (3) RE-APPOINTMENT ... | - | HKEx | ||
| 23.04. | BRII-B (02137): 2025 ANNUAL REPORT | - | HKEx | ||
| 16.04. | Brii Biosciences Files Arbitration in US Over Contract Dispute with Vir | 3 | AASTOCKS | ||
| 16.04. | BRII-B (02137): INSIDE INFORMATION IN RELATION TO ARBITRATION PROCEEDINGS | 2 | HKEx | ||
| 19.03. | Brii Biosciences Limited: Brii Biosciences Provides Corporate Updates and Reports Full Year 2025 Financial Results | 219 | PR Newswire | Advancing HBV Functional Cure Toward Key Phase 2b Data Readouts
Increasing Discovery Efforts to Drive Long-term Value Creation
Strong Cash Position Supporting Strategic... ► Artikel lesen | |
| 19.03. | BRII-B (02137): NOTIFICATION OF 2025 PFIC STATUS | - | HKEx | ||
| 19.03. | BRII-B (02137): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 | - | HKEx | ||
| 09.03. | BRII-B (02137): DATE OF BOARD MEETING | 1 | HKEx | ||
| 10.11.25 | BRII-B (02137): VOLUNTARY ANNOUNCEMENT PRESENTS LATE-BREAKING DATA FROM ONGOING PHASE 2 ENSURE STUDY AT AASLD 2025 | 1 | HKEx | ||
| 07.11.25 | BRII-B (02137): VOLUNTARY ANNOUNCEMENT PUBLICATION OF PHASE 2 ENSURE STUDY RESULTS IN NATURE MEDICINE | - | HKEx | ||
| 21.08.25 | Brii Biosciences Limited: Brii Biosciences Provides Corporate Updates and Reports 2025 Interim Financial Results | 188 | PR Newswire | Multiple Ongoing Phase 2b Studies Advancing HBV Functional Cure Strategy
Greater China Partnership with Joincare to Accelerate Development of Critical Care Antibiotic... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOGEN | 166,48 | -0,06 % | Ihre wichtigsten Termine: Alphabet, Meta, Microsoft, Amazon, Ebay, Biogen & Mercedes-Benz legen Zahlen vor | © Foto: Dall-EGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:45 Uhr, Schweiz:... ► Artikel lesen | |
| ILLUMINA | 103,50 | +0,37 % | Illumina Expands Collaboration With Labcorp To Advance Precision Oncology | SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), Wednesday announced an expanded collaboration with Labcorp to advance precision oncology through innovative applications of next-generation sequencing... ► Artikel lesen | |
| NANOREPRO | 1,530 | -2,55 % | NanoRepro: Guter Deal | Das ist offensichtlich: Gemessen an den nahezu identischen Kurszielen von 4,50 Euro (GBC) und 4,30 Euro (NuWays) lässt NanoRepro gegenwärtig viel Raum im Chart ungenutzt. So pendelt die Notiz seit Monaten... ► Artikel lesen | |
| CYTODYN | 0,252 | 0,00 % | CytoDyn Inc.: CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer | Program provides access to leronlimab for patients with limited treatment options while supporting ongoing clinical development VANCOUVER, Washington, April 27, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc.... ► Artikel lesen | |
| IMMUNIC | - | - | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenZAE000337051 Africa Bitcoin Corporation Ltd. 24.04.2026 ZAE000358925 Africa Bitcoin Corporation Ltd. 27.04.2026 Tausch... ► Artikel lesen | |
| ADAPTIVE BIOTECHNOLOGIES | 11,685 | +0,78 % | Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results | SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics... ► Artikel lesen | |
| GENPREX | 0,864 | -7,08 % | Genprex collaborators to present diabetes gene therapy data at May meeting | ||
| AMICUS THERAPEUTICS | 12,335 | 0,00 % | XFRA AM6: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILAMICUS THERAPEUTICS... ► Artikel lesen | |
| PERSONALIS | 4,351 | +1,09 % | Personalis presents ctDNA monitoring data at cancer research meeting | ||
| VITROLIFE | 9,640 | +0,89 % | Vitrolife AB: Interim report Q1, 2026: Strong growth in Consumables and Technologies | First quarter
Sales of SEK 807 (842) million, an increase of 5% in local currencies and 4% decrease in SEK.
Sales per region, in local currencies, were -1% in EMEA, +11% in Americas... ► Artikel lesen | |
| PLURI | 4,660 | -100,00 % | Pluri Inc.: Pluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private Placement | HAIFA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. ("Pluri" or the "Company") (Nasdaq, TASE: PLUR), a biotechnology company leveraging a proprietary cell-based platform across multiple commercial... ► Artikel lesen | |
| LEGEND BIOTECH | 20,000 | +2,04 % | H.C. Wainwright Reaffirms Buy Rating for Legend Biotech (LEGN) | ||
| ENVERIC BIOSCIENCES | 5,240 | 0,00 % | Lakewood-Amedex beruft CEO von Enveric in den Verwaltungsrat | ||
| ENANTA | 11,800 | +1,72 % | Enanta Pharmaceuticals, Inc.: Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026 | Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that... ► Artikel lesen | |
| NATURAL ALTERNATIVES INTERNATIONAL | 2,200 | +1,85 % | Natural Alternatives International Inc: Natural Alternatives International, Inc. Announces 2026 Q2 and YTD Results | CARLSBAD, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements... ► Artikel lesen |
BRII BIOSCIENCES LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,144 Euro und damit +0,70 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BRII BIOSCIENCES LTD finden Sie auf Wallstreet Online.